Phase 2 N=50 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=33 Chemotherapy for Patients With Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR]) — 0.182 proportion of responders
Phase 2 N=25 Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Leukemia · Lymphoma, Non-Hodgkin
Primary: Tumor Apoptosis — 7 Participants
Phase 2 N=38 Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
Breast Neoplasms · Breast Cancer
Primary: Overall Response Rate (ORR) — 45.16 percentage of participants
N/A N=128 Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence
Medication Adherence
Primary: Medication Adherence at Baseline and 6-month Follow-up Period — 59.4; 55.95 units on a scale
Phase 2 N=13 Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Osteosarcoma · Nephrotoxicity · Ototoxicity
Primary: Change in Urinary Biomarkers of Acute Kidney Injury (AKI) Between Pre-Treatment (Baseline), After CISplatin (C) Treatments, and After HDTMX Treatments — 1.7; 1.7; 2.1…
Phase 2 N=21 EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)
Head and Neck Cancer
Primary: Participants With Mucositis and Hematological Toxicities With the Addition of Radioprotector Amifostine — 16 participants
N/A N=280 Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose
Breast Neoplasms
Primary: Evaluation of the Occurrence of Nail Toxicity of Grade 2 of Common Toxicity Criteria for Adverse Effects V4.0 Evaluated at 8 Weeks Post Infusion of Docetaxel. — 26; 49…
Phase 3 N=260 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Phase 3 N=319 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
Cancer
Primary: Neurotoxicity Assessment at Baseline — 8.5; 7.3; 5.23; 4.58 units on a scale
N/A N=52 Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
Colorectal Cancer · Gastric Cancer · Esophageal Cancer
Primary: Unplanned Chemotherapy Treatment Delay — 16 Participants
Phase 2 N=54 Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
Laryngeal Cancer
Primary: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment — 27; 12 Participants
Phase 2 N=34 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Malignant Pleural Mesothelioma · Mesothelioma
Primary: Disease Control Rate (DCR) — 75 percentage of participants
Phase 2 N=18 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Leukemia-Lymphoma, Adult T-Cell
Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants
Phase 2 N=7 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Diffuse Mixed Cell Lymphoma · AIDS-related Diffuse Small Cleaved Cell Lymphoma
Primary: Overall Survival — 0; 0 Proportion of participants
Phase 1 N=30 Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Liver Cancer
Primary: Pharmacokinetics Profile-- Peak of Plasma Concentration (Dose-normalized) — 2.67; 3.68; 7.11; 0.08 ng/mL/mg — p=.036
Phase 2 N=32 Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Breast Cancer · Non-Hodgkin's Lymphoma
Primary: TNF-alpha Levels in Patients Receiving Doxorubicin Containing Chemotherapy — 3.55; 3.68; 2.95; 3.18 log(pg/ml) — p=0.014
Phase 2 N=46 The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts
Mucinous Pancreatic Cysts
Primary: Number of Participants With the Changing in Cyst Volume — 6; 12; 5; 4 Participants
N/A N=7 Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Primary: Relative Change in % pO2 — 12.3; 19; 24; 25.3 change in % oxygenation
Phase 2 N=27 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients — 13; 14 Participants — p=<.05
Phase 2 N=348 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants
N/A N=20 Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Lymphoma
Primary: Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group — 300; 250 ug/mL*hr
N/A N=63 Chronic Neuropathy Following Chemotherapy
Peripheral Nervous System Diseases · Chronic Pain
Primary: Chemotherapy-induced Peripheral Neuropathy — 21 participants
Phase 2 N=25 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Phase 2 N=30 Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
Breast Cancer · Breast Neoplasm
Primary: Number of Participants With Adverse Events — 9; 20 Participants
Phase 2 N=300 STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
Heart Failure
Primary: The Percentage of Individuals in Each Group With a Significant Decline in the LVEF. — 22; 9 Participants
Phase 2 N=95 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
Phase 2 N=102 Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 28; 31 percentage of patients
Phase 2 N=46 Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
Liver Cancer
Primary: Number of Participants With Complete Response or Partial Response (Objective Response), as Assessed According Central Review — 22; 22 Participants
Phase 2 N=12 PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy
Cancer
Primary: Percent Change in Tc-94m Sestamibi Body Weight Standardized Uptake Value (SUV) Maximum in Tumor Tissue Before and After Administration of Tariquidar, a P-glycoprotein…